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Background: We have previously shown that in healthy young men, a less favorable body composition is
associated with higher free triiodothyronine (fT3) levels within the euthyroid range. Besides, a higher free-
triiodothyronine-to-free-thyroxin (fT3-to-fT4) ratio has been related to a less favorable metabolic phenotype and
more placental growth in pregnant women. In the present study, we therefore investigated whether serum
thyrotropin (TSH), thyroid hormone levels, and the fT3-to-fT4 ratio are associated with metabolic and adiposity-
related cardiovascular risk markers in a healthy population of middle-aged euthyroid men and women.
Methods: Thyroid parameters were measured in 2524 generally healthy subjects from the Asklepios Study (35–
55 years, mean age 46 years). Analyses were restricted to 2315 subjects (1138 women and 1177 men), not using
thyroid medication, not having anti-TPO levels above clinical cutoff values or TSH levels outside the reference
range (0.27–4.2 mU/L). Twenty-seven percent of the women and 47.5% of the men were overweight, while 13%
of women and 17% of men were obese. Twenty percent of the subjects were active smokers. Serum thyroid
function parameters were determined by electrochemiluminescence.
Results: fT3 and the fT3-to-fT4 ratio were positively related to body mass index (BMI), waist circumference, and
components of metabolic syndrome, that is, triglycerides, systolic and diastolic blood pressure, and fasting
plasma glucose, and negatively with HDL-cholesterol levels, whereas fT4 was negatively associated with BMI,
waist circumference, and triglycerides ( p < 0.001). TSH related positively with total cholesterol levels ( p < 0.01),
triglycerides, and systolic and diastolic blood pressure ( p < 0.001). The fT3-to-fT4 ratio was further positively
associated with the adiposity-related inflammation markers interleukin-6 and high-sensitivity C-reactive protein
and to pulse wave velocity. All associations were adjusted for sex, age, height, and smoking, and most asso-
ciations persisted after additional adjustment for weight or waist circumference.
Conclusion: In healthy euthyroid middle-aged men and women, higher fT3 levels, lower fT4 levels, and thus a
higher fT3-to-fT4 ratio are consistently associated with various markers of unfavorable metabolic profile and
cardiovascular risk.
Introduction
The interrelation of thyroid hormones (THs) andweight status is widely recognized. Thyroid hormone
increases basal metabolic rate, which generally leads to
weight loss in overt hyperthyroidism and might cause weight
gain in hypothyroidism (1). Weight status could also exert an
influence on circulating TH, since elevations in thyrotropin
(TSH) and free triiodothyronine (fT3), generally without ef-
fects on free thyroxine (fT4), were shown in obese subjects
(2–5). Also, in a more general (nonobese) euthyroid popula-
tion, associations of TSH and thyroid hormones with body
composition and/or metabolic parameters have been found
(2,6–12). Higher TSH levels within the normal range have
been related to blood pressure (13–17) and different lipid
parameters (14,18–20).
Regarding free thyroid hormones, results might appear
contradictory at first sight. On the one hand, lower fT4 levels
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have been related to (components of ) metabolic syndrome
(7,11,12), whereas higher fT3 levels have been linked to body
fat and different metabolic parameters (2,6,8–10). A higher
fT3-to-fT4 ratio has been related to a less favorable metabolic
phenotype and more placental growth in pregnant women
(21), which led us to hypothesize that this ratio could also be
associated with metabolic markers in the general population.
However, to our present knowledge, this has not yet been
investigated.
Finally, evidence exists that both subclinical (SC) hypothy-
roidism as well as SC hyperthyroidism are associated with an
increased cardiovascular risk and mortality (22–29). Some
studies have also reported on positive associations of TSH
and/or TH concentrations, even within the euthyroid range,
with more specific cardiovascular risk parameters (30–32). One
study showed a positive association between excess fT3 and
the prevalence and incidence of coronary events (33), whereas
another study reported an inverse association of fT4 levels with
coronary artery calcifications in healthy euthyroid subjects (34).
Therefore, in this population of 2315 healthy, euthyroid
middle-aged men and women, we aimed to assess associa-
tions of fT3, fT4, and TSH levels, and the fT3-to-fT4 ratio with
different metabolic indices. Furthermore, we investigated
whether these thyroid parameters are associated with other
adiposity-related cardiovascular risk markers, namely high
sensitivity C-reactive protein (hs-CRP), interleukin 6 (IL-6),
and pulse wave velocity, and whether these associations were
dependent on body weight.
Methods
Study population
The Asklepios Study is an ongoing population study fo-
cused on the interplay of aging, cardiovascular hemody-
namics and the emergence of cardiovascular disease. Subjects
were randomly sampled from the twinned Belgian commu-
nities of Erpe-Mere and Nieuwerkerken (Europe). Study de-
sign, in- and exclusion criteria, study components, and
baseline characteristics of the population have been described
in detail before (35). The cohort (n = 2524; 50.5% female) is a
population-representative random sample between 35 and 55
years, free from overt cardiovascular disease when entering
the study. The cross-sectional data of the present investigation
were acquired during the first measuring round (2002–2004).
The study was approved by the medical ethical committee of
Ghent University Hospital. All participants gave written in-
formed consent prior to enrollment. Data collection and
measurements have been described previously (35–37).
Individuals receiving thyroid hormone substitution or an-
tithyroid drugs, having TPO antibodies above clinical cutoff
for positivity (i.e., 35 U/L for the assay used), or with TSH
levels outside the reference range of our laboratory (0.27–
4.2 mU/L) were excluded from the analyses, leaving 2315
subjects (1138 women and 1177 men) for inclusion in the
present investigation.
Measurements
Body weight (kg) was measured in light indoor clothing.
Standing height (m) was measured using a wall-mounted
Harpenden stadiometer. Body mass index (BMI) is defined as
the body weight divided by the square of the body height.
Waist circumference (cm) is defined as the abdominal cir-
cumference located in the middle between the lower rib and
the iliac crest, hip circumference (cm) as the widest part of the
buttocks or hips. The waist:hip ratio is the waist circumfer-
ence divided by the hip circumference.
Blood pressure was recorded using bilateral triplicate
measurements (1 min intervals) on a rested, sitting subject
using a validated and calibrated oscillometric Omron HEM-
907 device (Omron Healthcare Co. Ltd., Kyoto, Japan). Blood
pressure values of these six readings were averaged, and the
mean value is used throughout the study.
The International Diabetes Federation’s (IDF) definition of
metabolic syndrome is defined as central obesity (i.e., waist
circumference ‡ 94 cm in men or ‡ 80 cm in women) plus any
two of the following four factors: (i) high triglycerides (i.e.,
‡ 150 mg/dL) or specific treatment for this lipid abnormality;
(ii) low HDL cholesterol (i.e., < 40 mg/dL in men or < 50 mg/
dL in women) or specific treatment for this lipid abnormality;
(iii) high blood pressure (i.e., ‡ 130/ ‡ 85 mmHg) or antihy-
pertensive treatment; (iv) high fasting plasma glucose con-
centration (i.e., ‡ 100 mg/dL) or previously diagnosed type 2
diabetes (38).
All subjects underwent an ECG-gated echographic exami-
nation of the carotid and femoral arteries (VIVID 7; GE
Vingmed Ultrasound, Horten, Norway). Flow was recorded
with a pulse wave Doppler using a 10–12 MHz vascular linear
probe, and the flow measurement site was marked and re-
corded. Carotid–femoral pulse wave velocity (PWV) was es-
timated as (DLS-F -DLS-C)/(DTQ-F -DTQ-C) with DLS-F and
DLS-C the distance measured from sternum notch to femoral
and carotid measuring sites respectively. DTQ-F and DTQ-C are
the time delay between the start of the QRS complex and the
upstroke of flow measured with Doppler echography in the
femoral and carotid artery (39,40).
Biochemical determinations
Blood samples were obtained throughout the day after six
hours fasting and refraining from smoking. All serum samples
were stored at - 80C until batch analysis. Thyroid hormone
function tests (TSH, fT3, fT4, and TT3) and TPO antibodies
were determined using immunoelectrochemiluminescence
(Roche reagents) on Cobas 411 (Roche Diagnostics GmbH,
Mannheim, Germany). The intra- and interassay CV % were
below 10% for all measurements. The fT3-to-fT4 ratio was
calculated by dividing fT3 (pg/dL) by fT4 (ng/dL) and further
dividing this value by 1000.
Serum glucose was assayed by a standard hexokinase en-
zymatic method. Total serum cholesterol was assayed by the
enzymatic colorimetric CHOD-PAP method of Allain et al.
(41). Serum HDL cholesterol was determined by the homog-
enous enzymatic method that uses dextrans sulfate and
polyethylene glycol-modified cholesterol esterase and cho-
lesterol oxidase. For serum triglycerides, the lipase kinetic
colorimetric reaction without glycerol correction was used.
LDL cholesterol was calculated using the classical Friedewald
formula LDL-C = (total C -HDL-C -TG)/5. When triglycer-
ides exceeded 350 mg/dL, a value for LDL-C was not calcu-
lated. High sensitive serum C-reactive protein was measured
by a high-sensitive, particle-enhanced immunoturbidimetric
method on an Integra 400 analyzer (Roche Diagnostics). CV
was < 3.0%. Serum interleukin-6 (IL-6) concentrations were
224 ROEF ET AL.
measured by an automated solid-phase, enzyme-labeled,
chemiluminescent sequential immunometric assay (IM-
MULITE 2000; Diagnostic Products Corp., Los Angeles, CA),
making use of murine monoclonal anti-IL-6 coated beads and
alkaline phosphatase-conjugated polyclonal sheep anti-IL-6
antibodies. Total CV was < 5.6%.
Statistical analysis
TSH, fT3, fT4, TT3, and the fT3-to-fT4 ratio were analyzed
both as a continuous variable and, for TSH and the FT3-to-FT4
ratio, also using quartiles (quartiles TSH women: 0.27–1.08,
1.09–1.54, 1.55–2.08, 2.09–4.2 mU/L; quartiles TSH men: 0.27–
1.03, 1.04–1.47, 1.48–1.99, 2.00–4.2 mU/L; quartiles fT3-to-FT4
ratio in women: < 0.22, 0.22–0.24, 0.24–0.26, > 0.26; quartiles
fT3-to-fT4 ratio in men: < 0.23, 0.23–0.25, 0.25–0.28, > 0.28).
All statistical analyses (linear regression analysis, one-way
analysis of variance [ANOVA], and logistic regression anal-
ysis) were performed using SPSS v19 (SPSS Inc., Chicago, IL).
Since men and women were analyzed together to increase the
power, analyses were first adjusted for sex. Additional ad-
justment for age, height, and current smoking status was
performed. A separate adjustment for weight or waist cir-
cumference was made in a second model. Statistical signifi-
cance was assumed for p-values < 0.05. Data are given as
mean – SD for normally distributed data or median (inter-
quartile range) for skewed data.
Results
Baseline characteristics of the study population
Characteristics of the study population, together with de-
scriptives for thyroid hormones, metabolic parameters, and
adiposity-related cardiovascular predictors are shown in Ta-
ble 1. Twenty-seven percent of the women and 47.5% of the
men were overweight (25 kg/m2 <BMI £ 29.9 kg/m2), and
12.8% of the women and 17% of the men were obese (BMI ‡
30 kg/m2). After adjustment for sex, age, and smoking, TSH
related negatively to fT4 (b = - 0.14, p< 0.0001) and positively
to the fT3-to-fT4 ratio (b= 0.10, p< 0.0001). fT3 was not sig-
nificantly associated with TSH.
Associations of TSH and thyroid hormones with body
composition and metabolic parameters
Analyses regarding the association between thyroid func-
tion indices and metabolic parameters and adiposity-related
cardiovascular risk markers pooled for men and women are
shown in Table 2. All analyses were adjusted for sex, age,
height, and current smoking status. Subjects taking lipid-
lowering (n= 142, 6%) or antihypertensive drugs (n= 237,
10%) were excluded from the analyses on lipid parameters
and blood pressure respectively.
fT3 and the fT3-to-fT4 ratio were positively related and fT4
was negatively related to BMI (Fig. 1), waist circumference,
and the waist:hip ratio ( p < 0.0001). Blood pressure (both
systolic and diastolic) was also positively related to fT3 and
the fT3-to-fT4 ratio ( p< 0.0001). The same was true for fasting
glucose levels, although the significance level for association
with TT3 was much lower ( p = 0.04). With regard to lipid
parameters, we observed a positive association between tri-
glycerides and fT3 and the fT3-to-fT4 ratio, whereas a nega-
tive association with fT4 was seen. The mirror image was
observed for HDL cholesterol, which was negatively associ-
ated with fT3 and the fT3-to-fT4 ratio. No associations were
seen for total cholesterol, and there was only a rather marginal
association between LDL cholesterol and TT3 ( p = 0.01).
TSH was positively associated with triglycerides, blood
pressure (both systolic and diastolic), and less significantly
with total cholesterol levels. Mean systolic and diastolic blood
pressure according to quartiles of TSH in men and women are
illustrated in Figure 2.
When an additional adjustment for weight or waist cir-
cumference was performed, most associations kept their sig-
nificance, except for the associations between fT3 and
triglycerides, between TT3 and HDL, and between the fT3-to-
fT4 ratio and diastolic blood pressure. Also, excluding the obese
subjects from the analyses did not alter the significance of most
associations, although the beta coefficients decreased. Analyz-
ing men and women separately, most associations remained
unchanged in the separate groups, except for associations of fT3
and fT4 with triglycerides, which were not present in men.
Table 1. Patient Characteristics
Women
(n = 1138)
Men
(n = 1177)
General characteristics
Age (years) 46 (41–51) 46 (41–51)
Height (cm) 163 – 6 176 – 7
Weight (kg) 65.4 – 11.6 81.1 – 12.2
BMI (kg/m2) 24.5 – 4.2 26.2 – 3.6
Smoking (active/
former/never) (%)
19/21/60 22/36/42
Overweight (25 £BMI
£ 29.9), n (%)
309 (27%) 559 (47.5%)
Obesity (BMI ‡ 30),
n (%)
146 (12.8%) 200 (17%)
TSH and thyroid hormones
TSH (mU/L) 1.53 (1.07–2.08) 1.47 (1.03–1.98)
fT4 (ng/dL) 1.25 (1.15–1.35) 1.34 (1.23–1.44)
fT3 (pg/dL) 300 (280–320) 338 (310–3.60)
TT3 (ng/dL) 120 (105–140) 118 (107–129)
fT3-to-fT4 ratio 0.24 (0.22–0.26) 0.25 (0.23–0.28)
Metabolic parameters
Fasting blood glucose
(mg/dL)
88 (83–93) 92 (87–98)
Triglycerides (mg/dL) 78 (59–111) 104 (76–153)
Total cholesterol (mg/dL) 212 (189–235) 217 (192–242)
LDL-cholesterol (mg/dL) 121 (101–144) 136 (113–159)
HDL-cholesterol (mg/dL) 71 – 17 56 – 14
Systolic BP (mmHg) 121 – 13 130 – 12
Diastolic BP (mmHg) 77 – 9 82 – 9
Waist circumference (cm) 80 – 11 94 – 10
Waist:hip ratio 0.77 (0.73–0.82) 0.92 (0.87–0.96)
Other cardiovascular risk markers
hs-CRP (mg/L) 1.4 (0.59–3.51) 1.03 (0.53–2.00)
IL-6 (pg/mL) 0.75 (0–1.5) 0.78 (0–1.56)
Pulse wave velocity (m/s) 6.3 (5.6–7.3) 6.3 (5.7–7.2)
Subjects on thyroid medication with TPO antibodies above clinical
cutoff and with TSH levels outside the reference range were excluded
from further analyses. Data are mean– SD or medians (first–third
quartiles) in case of non-Gaussian distribution. Conversion factor for
fT3 from pg/dL to pmol/L and for TT3 from ng/dL to nmol/L
is · 0.0154; conversion factor for fT4 from ng/dL to pmol/L is · 12.87.
BMI, body mass index; TSH, thyrotropin, BP, blood pressure,
hs-CRP, high sensitivity C-reactive protein; IL-6, interleukin 6.
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Associations of thyroid hormones with the presence
of metabolic syndrome as a whole
Additionally, fT3 and fT4 and the fT3-to-fT4 ratio were
related to the presence of metabolic syndrome as a whole
(according to the IDF criteria) (fT3: standardized OR = 1.3,
p < 0.0001; fT4: standardized OR= 0.9, p= 0.008; fT3-to-fT4
ratio: standardized OR= 1.5, p < 0.0001). All associations were
adjusted for sex, age, height, and current smoking status.
Associations between thyroid hormones
and other cardiovascular risk markers
The IL-6 levels were negatively related to fT4 levels and
positively to TT3, TSH, and to the fT3-to-fT4 ratio in a linear
regression model (Table 3). The associations with fT4 and the
fT3-to-fT4 ratio remained significant when additionally ad-
justing for weight or waist circumference.
For hs-CRP, the findings were essentially similar, that is, a
negative association with fT4 and a positive association with
the fT3-to-fT4 ratio. In addition, a positive relation with fT3
levels was observed, although the association with fT3 was
lost when additionally adjusting for weight.
Carotid-femoral pulse wave velocity (reflecting vascular
stiffening) displayed positive associations with fT3 as well as
with the fT3-to-fT4 ratio, even after adjustment for weight or
waist circumference.
Exclusion of obese subjects from the analyses did not alter
the observed associations with IL-6, hs-CRP, and pulse wave
velocity. When men and women were analyzed separately,
only the positive associations of hs-CRP and IL-6 with the fT3-
to-fT4 ratio remained significant in both sexes.
Discussion
The main finding from this cross-sectional study in 2315
euthyroid middle-aged men and women is that in the general
population a higher conversion of fT4 to fT3, as inferred from
the fT3-to-fT4 ratio, is a marker of an unfavorable metabolic
Table 2. Associations Between Thyroid Hormones and Metabolic Parameters (Pooled Men and Women)
TSH fT3 TT3 fT4 fT3:fT4
Dependent variable b p b p b p b p b p
BMI 0.03 0.1 0.12 < 0.0001{ 0.18 < 0.0001{ - 0.10 < 0.0001{ 0.19 < 0.0001{
Waist circumference 0.02 0.2 0.13 < 0.0001{ 0.16 < 0.0001{ - 0.08 < 0.0001{ 0.18 < 0.0001{
Waist:hip ratio 0.02 0.2 0.10 < 0.0001{ 0.10 < 0.0001{ - 0.05 < 0.0001{ 0.08 < 0.0001{
Systolic RR 0.10 < 0.0001{ 0.14 < 0.0001{ 0.16 < 0.0001{ - 0.02 0.4 0.12 < 0.0001{
Diastolic RR 0.10 < 0.0001{ 0.12 < 0.0001{ 0.12 < 0.0001{ 0.01 0.6 0.09 < 0.0001{
Triglycerides 0.08 < 0.0001{ 0.07 0.005{ 0.12 < 0.0001{ - 0.07 0.002{ 0.11 < 0.0001{
Total cholesterol 0.06 0.008{ - 0.05 0.045 - 0.03 0.2 - 0.01 0.6 - 0.02 0.3
LDL-cholesterol 0.3 0.2 - 0.01 0.8 - 0.05 0.01{ 0.01 0.8 - 0.01 0.7
HDL-cholesterol - 0.01 0.5 - 0.12 < 0.0001{ - 0.06 0.003{ 0.03 0.1 - 0.12 < 0.0001{
Fasting blood glucose - 0.01 0.6 0.12 < 0.0001{ 0.04 0.04* - 0.03 0.1 0.12 < 0.0001{
Reported values are betas and results from linear regression analysis with metabolic parameters as dependent variables and thyroid
parameters as independent variables. Betas are scaled; an adjustment for age, height, current smoking, and sex was performed (except for
BMI, which was only adjusted for age, sex, and smoking). For all lipid parameters, an exclusion of subjects on lipid-lowering drugs, and for
blood-pressure parameters, an exclusion of subjects on antihypertensive treatment, was made. Significant associations are indicated in bold.
*0.01< p £ 0.05; {0.001< p£ 0.01; {p£ 0.001.
FIG. 1. Mean BMI according to quartile of the FT3-to-FT4 ratio in women and in men. p-Value results from ANOVA
(analysis of variance, between categories).
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profile, with a higher BMI, waist circumference, waist:hip
ratio, blood pressure, triglycerides, fasting glycemia, and
lower HDL levels. Besides, this fT3-to-fT4 ratio was positively
related to IL6, hs-CRP, and carotid-femoral pulse wave ve-
locity. These observations remained significant after addi-
tional adjustment for weight or waist circumference and after
exclusion of obese subjects (BMI > 30 kg/m2), which shows
that the associations are not driven by the obese subjects so-
lely. Finally, most associations were present in both women
and men when considered separately.
Our observations of positive associations between fT3 and
metabolic and cardiovascular parameters, while fT4 was
negatively related to the latter parameters, might seem
counterintuitive. However, the interrelation of THs within
normal range with body composition and metabolic status is
complex, and apparently discordant results have been re-
ported.
On the one hand, inverse associations between fT4 and
different metabolic parameters have been observed (7,8,11,
12,42,43). Shon et al. observed negative associations between fT4
within the normal range and BMI (43). Roos et al. have also
reported on associations between low normal fT4 levels and
increased insulin resistance and an unfavorable lipid profile in a
cross-sectional study of 2703 euthyroid adults (11). In another
cross-sectional study in 3148 subjects, fT4 was positively related
to HDL and inversely to waist circumference, HOMA-IR, and
insulin (12). Kim et al. reported that subjects in the highest fT4
quintiles had a significantly lower prevalence of metabolic
syndrome than those in the lowest fT4 quintile, but such dif-
ferences disappeared after adjustment for age (7). Finally, Ale-
vizaki et al. showed that fT4 levels were negatively associated
with the abdominal subcutaneous fat layer thickness as well as
with the subcutaneous fat/periperitoneal fat ratio (42). How-
ever, other studies observed no associations between fT4 and
body weight or BMI (8,44).
On the other hand, fT3 has been related positively to body
fat mass and various metabolic parameters (2,5,8–10). In ob-
ese subjects, positive associations between fT3 and BMI, waist
circumference, and insulin were observed (2,5,9). Also in a
more general population, positive associations between fT3
and metabolic status have been observed (8,10). We previ-
ously reported on positive associations of BMI, fat mass, and
insulin resistance with fT3 in healthy euthyroid young men
(10). Recently, Kithara et al. also described positive associa-
tions between body fatness and fT3 (8).
These findings, together with observations of Bassols et al.
(21), who described a less favorable metabolic phenotype and
more placental growth in pregnant women with lower fT4
FIG. 2. Mean systolic and diastolic blood pressure according to quartiles of TSH (within reference range). p-Values result
from overall ANOVA.
THYROID HORMONES, METABOLIC PROFILE AND CARDIOVASCULAR RISK 227
levels and a higher fT3-to-fT4 ratio, have led us to hypothesize
that a higher conversion of fT4 to fT3, as inferred from
changes in the fT3-to-fT4 ratio, might be an indicator of an
unfavorable metabolic profile.
Several mechanisms can be postulated. First, prior studies
have suggested changes in deiodinase (DIO) 1 and/or 2 ac-
tivity in subjects with a relatively higher fat mass and/or a
less favorable metabolic profile, hereby leading to higher
conversion of fT4 to fT3. Indeed, under conditions of in-
creasing adiposity, a higher DIO1 activity in white adipose
tissue, through stimulation by leptin, has been shown in mice
(45). Also in humans, Ortega et al. have shown an increase in
DIO1-activity in hypertrophic white adipose tissue (46). DIO2
contributes to the activation of UCP-1 and thermogenesis and
is typically present in brown adipose tissue (47). We did not
find any studies reporting changes in DIO2 activity in healthy
subjects with a relatively higher fat mass. Nevertheless, DIO2
expression was shown to be increased in the dorso-cervical
subcutaneous adipose tissue among patients with HIV lipo-
dystrophy, particularly those with increased visceral adipos-
ity, and this increased DIO2 expression was positively
associated with energy expenditure (48).
Second, an adverse metabolic profile could theoretically
also lead to an altered thyroid hormone secretion by the
thyroid gland itself, with a relatively higher T3-secretion.
However, to the best of our knowledge, there are presently no
literature data in support of this hypothesis.
Third, since both higher TSH levels as well as a higher fT3-
to-fT4 ratio can indicate a lower iodine pool, and since TSH
was also positively related to the fT3-to-fT4 ratio, another
mechanism underlying the higher fT3-to-fT4 ratio (and the
higher TSH levels) in subjects with a less favorable metabolic
profile could be a lower iodine intake in the diet or a decreased
absorption. Nevertheless, we found no studies indicative of a
lower iodine intake in obesity.
Our findings of associations between TSH and blood
pressure and lipid parameters are in line with several large
epidemiological studies that also showed a positive associa-
tion between TSH within the reference range and (systolic and
diastolic) blood pressure (13,15–17). Itterman et al. (16) sug-
gested that the effect of variation in TH levels on blood
pressure is only a direct short-term effect, since only associa-
tions with current and not incident hypertension were found
in their study. Concerning the lipid status, overt hypothy-
roidism is associated with hyperlipidemia, and even sub-
clinical hypothyroidism has been related to alterations in
plasma lipids (49–52). Large observational studies evaluating
associations between normal-range TSH and lipids have also
shown positive relations with triglycerides, total and LDL
cholesterol (12,18), and a negative association with HDL (18).
Finally, Wang et al. (20) demonstrated a positive linear asso-
ciation between increasing levels of TSH within the normal
range and total cholesterol and triglycerides, which according
to the authors might be caused both by a direct effect of TSH
as well as through an indirect effect via circulating THs. A
proposed mechanism for direct effects of TSH involves TSH
receptors on hepatocytes and the upregulation of hepatic 3-
hydroxy-3-methyl glutaryl coenzymeA reductase, hereby
promoting cholesterol synthesis in the liver (20). Remarkable
in our study is that TSH was related to total but not to LDL-C
or HDL-C, suggesting an association with remnant choles-
terol, or non-HDL, non-LDL cholesterol. (Subclinical) hypo-
thyroidism has indeed been associated with elevated serum
concentrations of remnant lipoproteins, an effect that is re-
versible with L-T4 treatment (52). Of course, the associations
of TSH and lipid levels in our study may also be coincidental
and not causally related.
We further observed positive associations of the fT3-to-fT4
ratio with the adiposity-related markers of inflammation—IL-
6 and hs-CRP—and with carotid-femoral pulse wave velocity,
a marker of arterial stiffness, which persisted after additional
adjustment for weight or waist circumference. Basically, our
results suggest that a higher TSH, fT3, and fT3-to-fT4 ratio,
within the euthyroid range, are associated with a higher car-
diovascular risk. Peters et al. (33) showed earlier an excess of
coronary events in subjects with elevated fT3 levels, whereas
fT4 levels were inversely associated with coronary artery
calcifications in euthyroid healthy men, independent from
conventional CV risk factors in another study (34). We pro-
pose that a relatively higher fT3-to-fT4 ratio might also be
considered as a potential indicator of increased cardiovascu-
lar risk, although we presume that this effect results at least in
part from the less favorable body composition and metabolic
parameters associated with this higher fT3-to-fT4 ratio, and,
of course, this concept needs validation in a prospective set-
ting.
The strengths of this study are the large number of subjects,
together with the extensive phenotypic characterization,
which includes both an elaborated set of metabolic cardio-
vascular parameters, as well as a complete thyroid status as-
sessment with measurements of TSH, free thyroid hormones,
TT3, and thyroid antibodies.
The novelty of our results is that we extend the findings of
Bassols et al. (21)—who stated that the fT3-to-fT4 ratio is
Table 3. Associations Between Throid Hormones and Other Cardiovascular Risk Parameters
TSH fT3 TT3 fT4 fT3:fT4
Dependent variable b p b p b p b p b p
IL-6 0.02 0.04* 0.04 0.07 0.11 < 0.0001{ - 0.06 0.004{ 0.09 < 0.0001{
hs-CRP 0.04 0.07 0.07 0.001{ 0.35 < 0.0001{ - 0.12 < 0.0001{ 0.16 < 0.0001{
Pulse wave velocity 0.06 0.1 0.09 < 0.0001{ 0.09 < 0.0001{ 0.02 0.4 0.07 < 0.0001{
Reported values are betas and results from linear regression analysis with cardiovascular risk parameters as dependent variables and
thyroid parameters as independent variables. Betas are scaled; an adjustment for age, height, current smoking, and sex was performed.
Significant associations are indicated in bold.
*0.01< p £ 0.05; {0.001< p£ 0.01; {p£ 0.001.
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associated with an unfavorable metabolic profile in pregnant
women—to a population of middle-aged euthyroid women
and men. Besides, the associations with different cardiovas-
cular risk markers reinforce our observations.
The limitations of our study include the lack of a precise
assessment on body composition, such as by dual X-ray ab-
sorptiometry (DXA). Besides, the fact that blood samples were
taken throughout the day after only six hours of fasting instead
of an entire night fasting may have influenced increased levels
of TG and therefore LDL-C as well. Also, exercise during the
day could have influenced lipid levels, but this would rather
have led to a decrease of TG and an increase in HDL. An im-
portant limitation consists in the cross-sectional design, which
does not allow us to make causal inferences from the observed
associations. Longitudinal follow-up is presently ongoing. Fi-
nally, it must be emphasized that this study was performed in a
relatively young population (mean age 46 years) in the context
of evaluating parameters associated with cardiovascular dis-
ease, and it might not be possible to extrapolate all our findings
to an older population.
In conclusion, in this population of 2315 euthyroid mid-
dle-aged men and women, we have shown robust positive
associations of TSH, fT3, and the fT3-to-fT4 ratio, and neg-
ative associations of fT4 with different components of an
unfavorable metabolic profile and other (adiposity-related)
cardiovascular risk markers. Whether the observed associa-
tions merely reflect metabolic effects on the regulation of
thyroid hormone levels, or might represent an adaptive re-
action to a less favorable metabolic profile, is presently un-
known.
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